AAAAAA

   
Results: 1-3 |
Results: 3
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Authors: Roberts, JD Shibata, S Spicer, DV McLeod, HL Tombes, MB Kyle, B Carroll, M Sheedy, B Collier, MA Pithavala, YK Paradiso, LJ Clendeninn, NJ
Citation: Jd. Roberts et al., Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks, CANC CHEMOT, 45(5), 2000, pp. 423-427
Predictors of optimal virological response to potent antiretroviral therapy
Authors: Powderly, WG Saag, MS Chapman, S Yu, G Quart, B Clendeninn, NJ
Citation: Wg. Powderly et al., Predictors of optimal virological response to potent antiretroviral therapy, AIDS, 13(14), 1999, pp. 1873-1880
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (TM) (nolatrexed dihydrochloride) given by 10-day oral administration
Authors: Jodrell, DI Bowman, A Rye, R Byrne, B Boddy, A Rafi, I Taylor, GA Johnston, A Clendeninn, NJ
Citation: Di. Jodrell et al., A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (TM) (nolatrexed dihydrochloride) given by 10-day oral administration, BR J CANC, 79(5-6), 1999, pp. 915-920
Risultati: 1-3 |